Nuclera has completed a $75m financing round to enable the continued commercialisation of its protein discovery technology.
The company's benchtop system, eProtein Discovery, has been designed to expedite the protein purification process.
eProtein Discovery will also enable the scale-up of protein production for the lab — whether cell-free or cell-based methods are used.
Through this novel round of financing, Nuclera will aim to distribute its system across the US and Europe.
According to the company, the eProtein Discovery system has already been installed in the labs at a range of CROs, as well as biotech and biopharma companies.
Dr Michael Chen, CEO and co-founder, Nuclera, said: “This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world.”
Elevage Medical Technologies' Chief Operating Officer Dr Michael Wasserman, who was a contributor to this project, added: “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process."
"The demand for Nuclera’s technology is expanding rapidly, as AI and structural biology continues to drive the pace of new discoveries in life sciences and drug development. Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe to address their need for bespoke, rapid and convenient delivery of quality proteins.”
Dr Jonathan Milner, Chair of the Nuclera Board of Directors, concluded: “The ability to screen multiple protein expression profiles and print purified proteins in as little as 24 hours will revolutionize laboratory workflows and make a demonstrable impact in research and drug discovery timelines."
"Aligning with Nuclera more closely following my appointment as Chairman of the Board, I am excited as the Company’s pioneering solution continues to be recognised by the industry and demonstrated through this funding round.”
